The following is a summary of the Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Matinas BioPharma reported a revenue of $1.1 million for 2023, primarily generated from collaborations with BioNTech and Genentech.

• Major expenses for the year amounted to $24.9 million, decreased from $27.8 million in 2022, mainly due to lower clinical trial expenses.

• The net loss for 2023 was estimated at $22.9 million or $0.11 per share, up from a net loss of $21.0 million or $0.10 in the prior year.

• The company reported income from selling unused New Jersey net operating losses and R&D tax credits of $0.5 million in 2023.

• Cash, cash equivalents, and marketable securities worth $13.8 million were part of company's holdings as of December 2023.

Business Progress:

• Matinas is in partnership discussions, aiming to advance MAT2203 into Phase III.

• Positive results were reported from the Compassionate/Expanded Use Access Program.

• The focus has been on advancements of MAT2203 and the lipid nano-crystal (LNC) platform.

• The LNC platform has shown promise with the potent chemotherapeutic agent, docetaxel.

• The company showed progress in research for understanding LNC uptake and effective cargo delivery within tumor cell lines.

• The company continues to maintain its presence on the NYSE American and is preparing for the upcoming milestones in Q2 of 2024.

More details: Matinas BioPharma IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.